Fabtech Techn. Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 26 Aug 2026 | Industrial Manufacturing | Market Cap: ₹490 Cr
Targeting 30% to 40% year-on-year revenue growth for the next few years, particularly FY26 and FY27. The company targets 30-40% year-on-year revenue growth for the next two years (FY26 and FY27), with potential for higher growth beyond FY27 without a defined ceiling.
From Fabtech Techn.'s Q2 FY26 earnings-call transcript · updated 26 Aug 2026.
Price
₹390
Market Cap
₹490 Cr
P/E Ratio
31.0
How does Fabtech Techn. rank in Industrial Manufacturing?
Compare Fabtech Techn. against every Industrial Manufacturing company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
- →Targeting 30% to 40% year-on-year revenue growth for the next few years, particularly FY26 and FY27.
- →Expecting to achieve ₹225 to ₹250 crore top-line in FY26.
- →Order book expected to be between ₹200 to ₹250 crore by March 2026.
- →Confident about continuing strong growth beyond FY27 without setting a ceiling.
- →Growth driven by expanding into new sectors beyond pharma (non-pharma sectors such as data centers, solar, electronics, food, and medical disposables).
- →Market expansion accompanied by increased capacity, including a new manufacturing unit in Hyderabad by March 2026.
- →Emphasis on reference building and market penetration while moving towards value engineering and product development.
- →Confident of maintaining a 30-40% growth rate and establishing presence as a sector-agnostic clean room provider.
📈 Profitability & Margins
- →The company targets 30-40% year-on-year revenue growth for the next two years (FY26 and FY27), with potential for higher growth beyond FY27 without a defined ceiling.
- →For FY26, revenue is expected between ₹225 to ₹250 crore, supported by a strong order book and execution pipeline.
- →PAT margin is projected to be around 7-8% from the second half of the current year onward, improving as reference creation stabilizes and volume increases.
- →Margin compression in the current year is due to investments in reference building, promotional expenses, and competitive pricing to capture market share.
- →As references solidify, the company expects to command premium pricing, leading to normalized and potentially higher margins in subsequent years.
- →The company is focusing on building long-term sustainable earnings through strategic investments and market expansion, especially in non-pharma segments.
🏗️ Capital Expenditure Plans
- →FTCL has pre-empted and ordered 2 roll forming machines and 1 automatic panel assembly line to meet rising demand for modular panels; the panel assembly line will be operational by Q1 FY27, adding capacity worth ₹100-120 crore.
- →The company is setting up a new manufacturing unit in Hyderabad, expected to be functional by March next year (FY27), to expand capacity.
- →Strategic investments include increasing stake in entities like Kelvin after milestones are met; plans to fund growth largely through unutilized working capital and sanctioned bank limits.
- →Focus on value engineering and R&D development to improve costing and margin sustainability.
- →Ongoing industry-academia collaboration with IIT-Bombay for certificate programs at factories, enhancing technical skills.
💰 Fundraising & Capital Structure
- →The company currently has banking limits of ₹22 crore with minimal utilization as of September 2025.
- →They have obtained sanction from bankers for an enhancement of ₹15 crore, increasing the total working capital limit to around ₹30-35 crore.
- →The working capital remains largely unutilized, and they have proactively applied for the limit enhancement to be prepared for growth.
- →No explicit mention of new equity fundraising was indicated.
- →The company plans to fund growth largely through enhanced and currently underutilized working capital debt facilities.
- →Investments in subsidiaries like Kelvin are tied to milestones and are internally funded.
📋 Order Book & Pipeline
- →Current order position stands at approximately ₹160 crores.
- →An additional ₹100-200 crores worth of orders expected to be added in the next six months.
- →Approximately ₹225 crores of very hot leads are in final stages, though conversion may be less than full amount.
- →Total pipeline includes about ₹800 crores of hot leads, moving towards very hot status.
- →Target to enter FY27 with an order book of around ₹250-300 crores.
- →Execution timelines: Pharma projects typically take 6-9 months; Non-pharma projects, 4-6 months.
- →Aim to bill at least 50-60% of the order book in the upcoming period.
Key Metrics
Frequently Asked Questions
What were Fabtech Techn. Q2 FY26 results?
Targeting 30% to 40% year-on-year revenue growth for the next few years, particularly FY26 and FY27. The company targets 30-40% year-on-year revenue growth for the next two years (FY26 and FY27), with potential for higher growth beyond FY27 without a defined ceiling.
What is Fabtech Techn. share price analysis?
Fabtech Techn. currently shows a neutral. The stock trades at a P/E of 31.0 with a market cap of ₹490 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fabtech Techn. planning capital expenditure?
FTCL has pre-empted and ordered 2 roll forming machines and 1 automatic panel assembly line to meet rising demand for modular panels; the panel assembly line will be operational by Q1 FY27, adding capacity worth ₹100-120 crore.
Keep Fabtech Techn. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.